A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Conclusions ABT-767 had an acceptable safety profile up to the established RP2D of 400  mg BID and dose-proportional PK. Patients withBRCA1 or BRCA2 mutation, HRD positivity, and platinum sensitivity were more sensitive to ABT-767.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research